Organisation paid for research Program year 2025 Source: CMS Open Payments

US Oncology Research LLC

Neither a doctor nor a teaching hospital

Research payments

$106,674,694

15,542 payments

Through program year 2025, US Oncology Research LLC is reported as receiving $106,674,694 in research payments, across 15,542 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $12,031,840 3,009
2024 Research $11,749,070 2,549
2023 Research $17,859,643 2,562
2022 Research $9,199,987 1,772
2021 Research $22,719,496 2,282
2020 Research $18,770,050 1,751
2019 Research $14,344,608 1,617

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $17,251,863 688 payments
  2. Genentech, Inc. $15,904,058 3,041 payments
  3. GlaxoSmithKline, LLC. $13,055,206 872 payments
  4. Pfizer Inc. $9,886,953 1,483 payments
  5. BeiGene, Ltd. $8,133,076 250 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $5,242,777 1,383 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $3,123,950 460 payments
  8. Mirati Therapeutics, Inc. $3,102,473 470 payments
  9. Gilead Sciences, Inc. $3,011,736 744 payments
  10. BioNTech SE $2,507,847 917 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Thera $11,661,000 744 payments
  2. A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer $6,377,275 205 payments
  3. A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma $6,098,965 154 payments
  4. Ember-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant VS Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for Er+, Her2- Early Breast Cancer With An Increased Risk of Recurrence $4,140,089 80 payments
  5. Morningsun $4,066,042 475 payments
  6. Single Agent GDC 9545 VS Endocrine Monotherapy Adjuvant Treatment in HR Ebc $3,844,838 1,047 payments
  7. A Randomized Openlabel Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab Msb0010718c in Combination With Andor Following Chemotherapy in Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100 $3,049,051 233 payments
  8. A Randomized Openlabel Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab in Combination With Chemotherapy Followed By Maintenance Therapy of Avelumab in Combination With the Poly Adenosine Diphosphate Adpribose Polymerase Parp Inhibitor Talazoparib in Patients With Previously Untreated Advanced Ovarian Cancer Javelin Ovarian Parp100 $2,765,576 237 payments
  9. Polarix $2,655,815 396 payments
  10. A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib $1,847,495 38 payments
What the money was spent on Research payments · program years 2019–2025
  1. Non-patient care $2,123,413 329 payments
  2. Patient care $1,303,279 239 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record